Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
Ginkgo Bioworks (NYSE: DNA) announced that CEO Jason Kelly will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced that CEO Jason Kelly will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PT. Kelly will discuss Ginkgo's biopharma capabilities, including its Ginkgo Enzyme Services and high throughput pooled screening for CAR-T designs. The company offers end-to-end services in cell programming across various sectors, including pharmaceuticals and food. Further details, including a webcast link, will be available on their investor relations website.
Positive
- CEO's presentation at a prestigious healthcare conference could enhance visibility.
- Focus on biopharma capabilities and end-to-end services may attract new clients.
Negative
- Lack of specific financial metrics or updates in the announcement.
Details
News Market Reaction – DNA
The recorded move for DNA in the trading session of this news was +0.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m. PT (2:15 p.m. ET). He plans to discuss Ginkgo's biopharma capabilities and end-to-end services offerings, including Ginkgo Enzyme Services and high throughput pooled screening for CAR-T designs, among other topics.
Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-41st-annual-jp-morgan-healthcare-conference-301712880.html
SOURCE Ginkgo Bioworks
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.